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ABSTRACT
Background. Chronic kidney disease (CKD) is a highly prevalent condition. Urologic disorders are known causes of CKD, but
often remain undiagnosed and underestimated also for their insidious onset and slow progression. We aimed to evaluate
the prevalence of urological unrecognized diseases in CKD patients by uroflowmetry.
Methods. We enrolled consecutive stable CKD outpatients. The patients carried out two questionnaires, the International
Prostate Symptom Score and Incontinence Questionnaire-Short Form, and they also underwent uroflowmetry, evaluating
max flow rate (Qmax), voiding time and voided volume values.
Results. A total of 83 patients (43 males, mean age of 59.86 13.3 years) were enrolled. Our study showed 28 males and 10
females with a significant reduction of Qmax (P<0.001) while 21 females reported a significant increase of Qmax (P<0.001)
with a prevalence of 49.5% of functional urological disease. Moreover, we showed a significant association between Qmax
and creatinine (P¼0.013), estimated glomerular filtration rate (P¼0.029) and voiding volume (P¼0.05). We have not shown
significant associations with age (P¼0.215), body mass index (P¼0.793), systolic blood pressure (P¼0.642) or diastolic blood
pressure (P¼0.305). Moreover, Pearson’s chi-squared test showed a significant association between Qmax altered with CKD
(v2 ¼1.885, P¼0.170) and recurrent infection (v2¼8.886, P¼0.012), while we have not shown an association with proteinuria
(v2¼0.484, P¼0.785), diabetes (v2¼0.334, P¼0.563) or hypertension (v2¼1.885, P¼0.170).
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Conclusions. We showed an elevated prevalence of urological diseases in nephropathic patients; therefore, we suggest to
include uroflowmetry in CKD patient assessment, considering the non-invasiveness, repeatability and low cost of
examination. Uroflowmetry could be used to identify previously unrecognized urological diseases, which may prevent the
onset of CKD or progression to end-stage renal disease and reduce the costs of management.
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INTRODUCTION
The prevalence of chronic kidney disease (CKD) with various
degrees of renal damage (stage 1/5 Kidney Disease Improving
Global Outcomes (KDIGO) is increasing worldwide, being esti-
mated 6–7.5% in Italy (CHARES study) and 13% in the world pop-
ulation [1]. Diabetes and hypertension are the most common
causes of CKD, but other causes such as urological diseases
have a prevalence that is not exactly known in adults [2]. These
pathologies can be congenital or acquired. The most frequent
are vesicoureteral reflux (VUR), which can determine the reflux
nephropathy, recurrent urinary tract infections (UTIs), which
may result in pyelonephritis, and urinary tract obstruction,
which can be caused by anatomical and functional alterations
[ureteropelvic junction syndrome, bladder neck stricture, con-
genital urethral valves, urethral stenosis, nephrolithiasis, ma-
lignancies and benign prostatic hyperplasia (BPH)], and the
overactive bladder, especially in the females [3, 4]. These pa-
thologies may present insidious onset and slow progression,
which make them difficult to identify and define despite well-
known complications. Hypertension, proteinuria, urine concen-
tration defects, hyperkalaemia, metabolic acidosis, focal and
segmental glomerulosclerosis and CKD are the most common
complications that have a significant impact on long-term renal
and cardiovascular prognosis [5, 6]. The aim of this study is to
evaluate the prevalence of urological diseases in the nephrology
department and their possible association with renal function,
diabetes, hypertension, recurrent infection and proteinuria.
MATERIALS ANDMETHODS
The study protocol was approved by the Local Clinical Research
Ethics Committee. The study conforms to the principles out-
lined in the Declaration of Helsinki and we obtained a written
consent from each patient before enrolment.
Study design and subjects
We performed an observational, cross-sectional study on 83 clini-
cally stable CKD outpatients, enrolled from January 2016 to
December 2016, at the University Hospital ‘Policlinico Umberto I’
of Rome, Sapienza University of Rome, Italy. The study included
patients with CKD on conservative therapy [estimated glomerular
filtration rate (eGFR) 90 mL/min], Stage 1/5, and/or proteinuria,
and/or hypertension and/or recurrent UTIs. Statins, antihyper-
tensive, antiplatelet therapies and/or therapies with calcium, cal-
citriol and phosphate binders were continued in all patients
included in the study. We recorded the anamnesis and excluded
patients with urological or malformative pathologies and second-
ary nephropathies already known, severe infectious pathologies
or malignancy in progress, patients with severe heart disease
(Class IV New York Heart Association) or acute cardiac failure, de-
generative neurological or psychiatric diseases, which did not al-
low the tests to be carried out properly, and acute coronary
syndrome or stroke, within 3 months before the study. We did
not enrol patients who refused to give consent or patients with
missing data. The patients carried out two questionnaires, the
International Prostate Symptom Score (I-PSS) [7, 8] and
Incontinence Questionnaire-Short Form (ICIQ-SF) [9], and they
also underwent uroflowmetry. eGFR was calculated with the ab-
breviated Modification of Diet in Renal Disease formula,
expressed in mL/min/1.73 m2 as defined by Levey et al. [10].
Anthropometric assessment
Body weight was determined to the nearest 0.1 kg using a cali-
brated digital scale. Body mass index (BMI) was calculated by
the formula: [weight (kg)/height2 (m2)].
Blood pressure measurements
Blood pressure (BP) measurements were made in the dominant
arm after 10 min of rest in the sitting position using a standard
automatic sphygmomanometer and cuffs adapted to the arm
circumference, according to the British Hypertension Society
guidelines [11]. The mean of the three measurements was
recorded for statistical analyses. The systolic BP (SBP) and dia-
stolic BP (DBP) levels were taken as the points of appearance
and disappearance of Korotkoff sounds, respectively.
Hypertension was defined as SBP 140 mmHg or DBP
 90 mmHg on repeated measurements. We have also calcu-
lated ankle brachial pressure index, the measurement of the ra-
tio of SBP in the ankle and in the arm (normal value 0.9–1).
Laboratory measurements
Blood was sampled the morning after overnight fasting of at
least 12 h, for laboratory assessment. In all patients, the levels
of fasting plasma glucose (mg/dL), haemoglobin (g/dL), total se-
rum cholesterol (mg/dL), triglycerides (mg/dL), high-density li-
poprotein (HDL) (mg/dL), creatinine (mg/dL), serum nitrogen
(mg/dL), serum uric acid (mg/dL), calcium (mg/dL), phosphorus
(mg/dL) and serum electrolytes (mEq/L) were measured using
standard automated techniques. Low-density lipoprotein cho-
lesterol (LDL) (mg/dL) was calculated using the Friedewald equa-
tion: LDL (mg/dL) ¼ total cholesterol – HDL  (triglycerides/5).
Urinalysis, urine culture and proteinuria 24 h (mg/24 h) was also
carried out.
I-PSS
This questionnaire was developed by experts at the
International Consultation on Prostatic Diseases, and it is uni-
versally accepted as an objective assessment tool for prostate
enlargement (prostatic hypertrophy) in urinary disorders [7].
A symptom index for BPH was developed and validated by a
multidisciplinary measurement committee of the American
Urological Association (AUA). The final AUA symptom index
includes seven questions covering frequency, nocturia, weak
urinary stream, hesitancy, intermittence, incomplete emptying
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and urgency. The AUA symptom index is clinically sensible, re-
liable, valid and responsive [8].
ICIQ-SF
The ICIQ-SF comprises three scored items and an unscored self-
diagnostic item. It allows the assessment of the prevalence, fre-
quency and perceived cause of urinary incontinence, and its im-
pact on everyday life. The ICIQ is a brief and robust
questionnaire that will be of use in outcomes and epidemiologi-
cal research as well as routine clinical practice [9]. The normal
value is <11.
Uroflowmetry
All patients carried out a uroflowmetry, with a commercially
available instrument (Dantec MedicalVR , the Dan Flow 1100-WiFi
version; Dantec Dynamics Ltd, a Nova Instruments Company,
Garonor Way, Royal Portbury, Bristol, UK), evaluating max
flow rate (Qmax) (20 < normal value < 35 mL/s), voiding time
(normal value<20 s) and voided volume (normal value>150 mL)
values [12].
Urodynamics is a tool of evaluating the pressure–flow rela-
tionship between the bladder and the urethra to assess the func-
tional status of the lower urinary tract. The main goal of
urodynamics is to aid in the correct diagnosis of lower urinary
tract dysfunction based upon its pathophysiology [13].
Urodynamic studies should assess both the filling and storage
phase as well as the voiding phase of bladder, and urethral func-
tion. Simple urodynamic tests involve performing non-invasive
uroflow studies, obtaining post-void residual (PVR) urine meas-
urements, the amount of residual urine in the bladder after a vol-
untary void and performing dual-channel cystometrography
(CMG). Currently, the normal values of the PVR are poorly de-
fined. However, most urologists agree that 50–100 mL volumes
constitute the lower threshold defining abnormal residual urine
volume [12]. CMG is the graphic recording of the pressure exerted
at varying degrees of filling of the urinary bladder. It measures
pressure generated by the bladder when voiding. A dual-channel
CMG is used to assess the first sensation of filling, fullness and
urinary urge. Bladder compliance and the evaluation of detrusor
contractions can also be noted during this filling CMG [14].
Statistical analysis
Data management and analysis were performed using IBMVR
SPSSVR Statistics 17 for WindowsVR software. The normality of
variables was tested using the Kolmogorov–Smirnov method for
normal distributions. All continuous variables were expressed
as mean 6 SD; categorical variables were expressed as number.
Student’s t-test or univariate analysis of variance was per-
formed to determine differences between groups. Chi-squared
test was used for comparison of categorical data. A probability
value of P< 0.05 was considered to be statistically significant.
Ethical approval and informed consent
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the
Institutional and/or National Research Committee at which the
studies were conducted and with the 1964 Helsinki Declaration
and its later amendments or comparable ethical standards.
Institutional Review Board approval has been obtained.
Informed consent was obtained from all individual participants
included in the study.
RESULTS
A total of 83 patients (43 males) with a mean age of 59.8613.3
were enrolled. Patient’s characteristics are shown in Table 1.
We have subdivided the sample according to the Qmax, voiding
time and voiding volume [12] (Table 2).
A total of 24 patients with normal Qmax (20–35 mL/s) showed
an eGFR of 81617 mL/min/1.73 m2, while 59 patients with Qmax
<20 mL/s showed an eGFR of 65625 mL/min/1.73 m2 and 25
patients with Qmax >35 mL/s showed an eGFR of 66625 mL/
min/1.73 m2 (P¼ 0.024; Table 2).
The anamnestic information was collected, in the males, us-
ing I-PPS, with an average score of 12.4 (moderate symptomatol-
ogy). In detail, 16.5% of the patients examined had a score <7
(mild symptomatology), while 50% and 33.5% of the patients
showed I-PSS scores, respectively, indicative of a moderate and
severe symptomatology. Moreover, 18 patients, males and
females, with impaired Qmax presented a pathological ICIQ-SF
with value >11, with a symptomatology that was irritative and
obstructive. However, although the symptomatology was rather
evident, only 22% had previously performed an urologic visit.
We have found a high prevalence of 49.5% of urological disease
in this study population. Also, we showed 28 males (66.6%) and
10 females (25.1%) with a significant reduction of Qmax
(P< 0.001) and 21 females (52.7%) with a significant increase of
Qmax (P< 0.001) with respect to the normal values. Moreover, we
showed an association between pathological Qmax (P< 0.001)
and voiding volume (P¼ 0.05) with an increase of creatinine
(P¼ 0.013) and reduced eGFR (P¼ 0.029), while we did not show
any significant associations with age (P¼ 0.215), BMI (P¼ 0.793),
SBP (P¼ 0.642) and DBP (P¼ 0.305) (Table 2). Furthermore
Pearson’s chi-squared test showed a significant association be-
tween pathological Qmax with CKD (v
2¼ 8.495, P¼ 0.004)
(Figure 1) and recurrent infection (v2¼ 8.579, P¼ 0.014), while we
did not show any association with proteinuria (v2¼ 0.484,
P¼ 0.785), diabetes (v2¼ 0.334, P¼ 0.563) and hypertension
(v2¼ 1.885, P¼ 0.170).
DISCUSSION
In this study, we showed a high prevalence of unrecognized
urological disease in nephropathic patients (49.5%). In particu-
lar, in the female population, we reported mostly a high Qmax,
with urgency urinary incontinence, indicating a possible over-
active bladder, or bladder filling phase disease or pelvic floor
dysfunction. Moreover, we showed a significant association
between pathological Qmax and reduced eGFR, which could be
Table 1. Patients’ characteristics
Patients (n) ¼ 83
Age (years) 576 13
Voiding volume (mL) 3606 156
Voiding time (s) 36.7 6 15.9
Max flow rate (mL/s) 26.0 6 4.0
Creatinine (mg/dL) 0.96 6 0.22
SBP (mmHg) 1336 17
DBP (mmHg) 816 10
eGFR (mL/min/1.73 m2) 816 17
BMI (kg/m2) 24.3 6 2.1
Data are shown as mean 6 SD.
BMI: Body Mass Index; DBP: Diastolic Blood Pressure; eGFR: estimated
Glemerular Filtration Rate; SBP: Systolic Blood Pressure.
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explained by increased intravesical pressure, especially in the
overactive bladder or detrusor overactivity [15, 16]. Already in
1981, McGuire et al. [17] recognized the important role of high
bladder pressure in myelodysplastic patients, and he identi-
fied in 40 cm H2O the limit value of the bladder, below which
no reflux occurred and only 10% of dilation happened, while
for higher values 68% of patients presented VUR and 81% ure-
teral dilation. Indeed, increased intravesical pressure initially
determines an increase in frequency and amplitude of ureteral
contractions, and subsequently, reflux and/or dilation. These
alterations remain reversible at an early stage, reducing the
pressure with antimuscarinic drugs and intermittent catheter-
ization, but afterwards ischaemic damage develops and detru-
sor muscle tissue becomes more rarefied and replaced by
collagenous tissue, reducing detrusor contractility [18].
Furthermore, the fibrosis is irreversible and can thicken the
bladder wall by narrowing the ureter resulting in uretero-
hydronephrosis. Gibbons [19] showed that high urinary tract
pressures should be considered a determining factor in the
pathophysiology of non-refluxing pyelonephritis, an insidious
disease that may lead to irreversible renal lesions, without re-
covery in advanced stages. Therefore, early diagnosis and ap-
propriate medical management could prevent possible
damage to long-term kidney function [20, 21]. In our study,
also patients with low Qmax, in particular males, showed a de-
creased eGFR, probably for the high incidence of bladder outlet
obstruction (BOO) after 50 years. Hong et al. [22] evaluated the
potential association between BPH and CKD in 2741 men pre-
senting with lower urinary tract symptoms secondary to BPH
of varying severity. Their results showed that only Qmax and
PVR urine volume were identified as independent predictors
of CKD, even if a decreased Qmax, with a history of hyperten-
sion and/or diabetes mellitus, were significantly associated
with CKD. Also Cho et al. [23] showed that increased PVR was
independently associated with a more rapid decline in renal
function in patients with Type 2 diabetes. The pressure–flow
relationship to diagnose obstruction is much better defined in
men, though recently it is used in both genders. The causes of
obstruction in women vary greatly, from anatomic as pelvic
prolapse, pelvic masses and iatrogenic obstruction after stress
incontinence, to functional as dysfunctional voiding and pri-
mary bladder neck obstruction [15]. Renal deterioration associ-
ated with chronic BOO is usually connected to impaired
compliance and high-storage pressures [24]. Jhang et al. [25]
evaluated the association between bladder function and CKD,
showing that the bladder mucosa of these patients, especially
in the advanced stage of CKD, presented a higher number of
apoptosis cells and a lower expression of E-cadherin and tight
junction of zonula occludens. The reduction of these two pro-
teins has been associated with urothelial dysfunction, a bar-
rier defect and an increase in intramucosal inflammation,
which could justify a decrease in bladder capacity, an in-
creased detrusor pressure and an increase in UTI. Therefore,
not only could urological dysfunctions worsen renal function,
but also CKD could favour urological alterations, in particular,
bladder dysfunction [26]. In fact, in our study we showed sig-
nificant associations between Qmax altered with CKD (Figure 1)
and with recurrent infections. We also showed low demand
for specialist urological visits, although the symptomatology,
both irritative and obstructive, was rather evident, perhaps
due to a lack of knowledge of urological expertise or to the be-
lief that some urologic disorders are normally due to a physio-
logical aging process. Low voided volumes need to be
considered in the light of volume/Qmax nomogram position.
Our study does not allow us to conclude if the urological ab-
normalities are the cause or consequence of CKD, but these
diseases may be associated, and therefore it is useful to con-
sider them in clinical practice [27].
Table 2. One-way analysis of variance comparison between pathological Qmax (max flow rate <20 and >35 mL/s) and normal Qmax (max flow









Age (years) 63.0 6 12.8 57.2 6 13.4 57.7 6 13.8 0.215
Voiding volume (mL) 273 6 110 356 6 155 334 6 133 0.050
Voiding time (s) 39.7 6 19.8 37 6 16.5 32.1 6 17.0 0.350
Creatinine (mg/dL) 1.3 6 0.55 0.93 6 0.22 1.16 0.40 0.013
SBP (mmHg) 136 6 19 136 6 16 138 6 15 0.642
DBP (mmHg) 80.7 6 10.1 81.96 11.1 80.7 6 10.1 0.305
eGFR (mL/min/1.73 m2) 65 6 25 81 6 17 66 6 25 0.024
BMI (kg/m2) 23.9 6 2.5 23.8 6 1.9 24.3 6 1.8 0.793
Proteinuria (mg/24 h) 96.1 6 78.2 65.8 6 16.1 72.9 6 55.6 0.125
Data are shown as mean 6 SD.
BMI: Body Mass Index; DBP: Diastolic Blood Pressure; eGFR: estimated Glemerular Filtration Rate; SBP: Systolic Blood Pressure.
FIGURE 1: Boxes represent the frequencies. The number of CKDþ patients with
pathological max flow rate was more than expected. Pearson chi-squared test
shows that there is a statistically significant association between CKDþ and
pathological max flow rate (v2 ¼ 8.495, P ¼ 0.004). Normal, patients with max
flow rate within the normal range; pathological, patients with max flow rate
outside the normal range; CKDþ, patients with chronic kidney disease; CKD,
patients without chronic kidney disease.










The limitations of our study are the relatively small, selective
cohort of CKD outpatients and the cross-sectional, single-centre
and observational design. Moreover, it is based on associations
with surrogate endpoints; indeed, it demonstrated an ‘associa-
tion’, rather than a ‘causality’ relationship, and therefore, the
data should be considered as hypothesis-generating. The gener-
ated hypothesis hence needs further prospective follow-up
studies with a larger number of patients and stronger endpoints
to show causality. Moreover, we have selected consecutive
patients with CKD, and/or proteinuria, and/or hypertension
and/or recurrent UTIs, and this may have influenced the results.
Another important limitation is that patients with advanced
CKD are not included.
CONCLUSIONS
Uroflowmetry study could be used as a first-level test to identify
possible urological disorders in nephropathic patients, espe-
cially considering the ease of execution, the repeatability, the
non-invasiveness and the low cost. Multidisciplinary care in
CKD patients could contribute to identify potential urological
diseases associated with CKD, to improve the standard of care
and clinical outcome.
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